Shuttle Pharma Provides First Quarter 2024 Corporate Update
May 14 2024 - 9:00AM
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle
Pharma”), a discovery and development stage specialty
pharmaceutical company focused on improving outcomes for cancer
patients treated with radiation therapy (RT), today provided a
corporate update in connection with the filing of its Quarterly
Report on Form 10-Q for the first quarter ended March 31, 2024.
Recent Highlights
Shuttle Pharma’s recent highlights include the following:
- Received FDA
approval to proceed with the Phase 2 Clinical Trial of
Ropidoxuridine for treatment of patients with glioblastoma, a
deadly malignancy of the brain with no known cure.
- Received central
institutional review board (“IRB”) approval for the Phase 2
clinical trial. For multicenter studies, the central IRB is the IRB
that conducts reviews on behalf of all study sites that agree to
participate in the centralized review process. For sites at
institutions that have an IRB that would ordinarily review research
conducted at the site, the central IRB should reach agreement with
each individual institution participating in centralized review and
those institutions' IRBs about how to apportion the review
responsibilities between local IRBs and the central IRB.
- Finalizing site
enrollment with up to six institutions with ‘first patient, first
dose’ expected in the second quarter of 2024.
- Created Shuttle
Diagnostics, Inc., a wholly owned subsidiary of Shuttle Pharma,
which will focus on developing a diagnostics laboratory to develop
its metabolite discovery platform technology and to support
multi-institutional clinical trials.
- Entered into an
exclusive agreement to license certain intellectual property from
Georgetown University to advance the Company’s predictive biomarker
program focused on developing a predictive diagnostic test for
prostate cancer patients who are considering elective radiation
therapy.
- Obtained an
exclusive license for PSMA-B intellectual property for advancing
research into diagnostic and therapeutic applications of metastatic
prostate cancer.
- At March 31, 2024,
Shuttle Pharma’s cash balance was approximately $4.2 million
(including cash, cash equivalents and marketable securities).
Recent Presentations
- Anatoly Dritschilo,
M.D., Chief Executive Officer of Shuttle Pharma, participated in a
presentation at the Planet MicroCap Showcase: VEGAS 2024 on May 1,
2023. A webcast link of the presentation can be found on the
investor relations page of the Company's website or accessed
HERE.
- Dr. Dritschilo also
recently participated in a fireside chat at the Lytham Partners
2024 Investor Select Conference and a webcasted presentation at the
Emerging Growth Conference.
- Posted updated
corporate slide presentation in May 2024 highlighting the
opportunity for both the company’s radiation sensitizer portfolio
as well as the diagnostic subsidiary.
“During the first quarter, we received the ‘Safe to Proceed’
letter from the U.S. Food and Drug Administration (FDA) to commence
our Phase 2 clinical trial of Ropidoxuridine for treatment of
patients with glioblastoma,” stated Shuttle Pharma’s Chairman and
CEO, Anatoly Dritschilo, M.D. “We have since received central IRB
approval for the trial, and are in the late stages of finalizing
agreements with six institutions participating in the trial. We
expect to have ‘first patient, first dose’ in the second quarter of
2024.”
“Beyond our focus on radiation sensitizers through both our
Ropidoxuridine and HDAC6 inhibitor development, we also announced
the formation of Shuttle Diagnostics, through which we aim to
develop pretreatment diagnostic blood tests for prostate cancer
patients. The first is a PC-RAD test for predicting outcomes
following RT for localized prostate cancer, while the second,
PSMA-B ligand, is a theranostic molecule offering diagnosis and
therapeutics for metastatic prostate cancer. There are currently no
available tests on the market that are predictive of success for a
specific treatment. We intend to develop Shuttle Diagnostics to
offer prognosis and guide treatment decisions, with the goal of
providing clinicians and patients with a means of measuring the
potential for success of RT for their cancer treatment.”
“For our Phase 2 clinical trial of Ropidoxuridine, we look
forward to finalizing site enrollment in the coming weeks and
beginning the process of entering our first patients on protocol.
The results of this Phase 2 clinical trial will determine clinical
efficacy of Ropidoxuridine as a radiation sensitizer with the goal
of increasing cancer cure rates, prolonging patient survival, and
improving the quality of life for patients suffering from
glioblastoma,” Dr. Dritschilo concluded.
About Shuttle Pharmaceuticals
Founded in 2012 by faculty members of the Georgetown
University Medical Center, Shuttle Pharma is a discovery and
development stage specialty pharmaceutical company focused on
improving the outcomes for cancer patients treated with radiation
therapy (RT). Our mission is to improve the lives of cancer
patients by developing therapies that are designed to maximize the
effectiveness of RT while limiting the side effects of radiation in
cancer treatment. Although RT is a proven modality for treating
cancers, by developing radiation sensitizers, we aim to increase
cancer cure rates, prolong patient survival and improve quality of
life when used as a primary treatment or in combination with
surgery, chemotherapy and immunotherapy. For more information,
please visit our website at www.shuttlepharma.com.
Safe Harbor Statement
Statements in this press release about future expectations,
plans and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
“forward-looking statements.” These statements include, but are not
limited to, statements concerning the development of our company.
The words “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “target,” “will,” “would” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including factors discussed in the “Risk
Factors” section of Shuttle Pharma’s Annual Report on Form 10-K for
the year ended December 31, 2023, filed with the SEC on March 20,
2024, as well other SEC filings. Any forward-looking statements
contained in this press release speak only as of the date hereof
and, except as required by federal securities laws, Shuttle
Pharmaceuticals specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Shuttle PharmaceuticalsAnatoly
Dritschilo, M.D., CEO240-403-4212info@shuttlepharma.com
Investor ContactsLytham Partners, LLCRobert
Blum602-889-9700shph@lythampartners.com
Shuttle Pharmaceuticals (NASDAQ:SHPH)
Historical Stock Chart
From May 2024 to Jun 2024
Shuttle Pharmaceuticals (NASDAQ:SHPH)
Historical Stock Chart
From Jun 2023 to Jun 2024